BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28960259)

  • 1. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
    Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
    Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
    Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
    Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant radiation therapy in small ductal carcinoma in situ.
    Cho WK; Choi DH; Kim H; Noh JM; Park W; Cha H
    Breast; 2019 Feb; 43():55-58. PubMed ID: 30448710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
    Pilewskie M; Olcese C; Patil S; Van Zee KJ
    Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of low-risk ductal carcinoma in situ in Southeast Asian women treated with breast conservation therapy.
    Wong FY; Wang F; Chen JJ; Tan CH; Tan PH
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):998-1003. PubMed ID: 24661651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
    Rakovitch E; Sutradhar R; Lalani N; Nofech-Mozes S; Gu S; Goldberg M; Hanna W; Fong C; Paszat L
    Breast Cancer Res Treat; 2019 Nov; 178(1):169-176. PubMed ID: 31325071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    ; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
    J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
    Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
    JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
    Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
    Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy.
    Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Gu S; Fong C; Tuck A; Youngson B; Miller N; Done SJ; Chang MC; Sengupta S; Elavathil L; Jani PA; Bonin M; Lalani N; Paszat L
    Breast; 2018 Feb; 37():181-186. PubMed ID: 28781102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is higher dose radiation necessary for positive resection margin after breast-conserving surgery for breast cancer?
    Cho WK; Choi DH; Park W; Kim H; Cha H
    Breast; 2019 Oct; 47():16-21. PubMed ID: 31265973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
    Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
    Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy.
    Rudloff U; Brogi E; Reiner AS; Goldberg JI; Brockway JP; Wynveen CA; McCormick B; Patil S; Van Zee KJ
    Ann Surg; 2010 Apr; 251(4):583-91. PubMed ID: 20224381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe.
    Wickberg Å; Liljegren G; Killander F; Lindman H; Bjöhle J; Carlberg M; Blomqvist C; Ahlgren J; Villman K
    Eur J Surg Oncol; 2018 Jul; 44(7):951-956. PubMed ID: 29709338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
    Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
    JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy.
    Laird J; Lok B; Siu C; Cahlon O; Khan AJ; McCormick B; Powell SN; Cody H; Wen HY; Ho A; Braunstein LZ
    Ann Surg Oncol; 2018 Jan; 25(1):154-163. PubMed ID: 29094250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
    Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
    Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.